Equities Analysts Set Expectations for ARWR FY2027 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a report issued on Monday, July 27th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings per share of ($3.35) for the year, up from their previous forecast of ($3.37). HC Wainwright has a “Buy” rating and a $115.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2028 earnings at ($3.12) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at $4.64 EPS.

Other equities research analysts also recently issued reports about the stock. Piper Sandler restated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Sanford C. Bernstein lifted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, JPMorgan Chase & Co. increased their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.08.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $85.78 on Wednesday. The stock has a market cap of $12.08 billion, a PE ratio of -39.90 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The firm has a 50-day moving average of $78.43 and a 200-day moving average of $70.26. Arrowhead Pharmaceuticals has a 52-week low of $15.01 and a 52-week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million for the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.75 earnings per share.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada increased its position in shares of Arrowhead Pharmaceuticals by 30.2% in the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 10,496 shares during the period. AQR Capital Management LLC bought a new position in Arrowhead Pharmaceuticals in the 1st quarter valued at about $514,000. Goldman Sachs Group Inc. increased its holdings in Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after buying an additional 447,456 shares during the period. Empowered Funds LLC raised its position in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 979 shares in the last quarter. Finally, Focus Partners Wealth lifted its holdings in shares of Arrowhead Pharmaceuticals by 1,339.5% during the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 15,123 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.